Market Overview

Integra LifeSciences Receives FDA Clearance for Expanded Indication for Spinal Device

Share:
Related IART
Integra LifeSciences to Acquire Total Ankle Replacement and Silastic Toe Replacement Product Portfolios from Tornier N.V.; Amount of Cash Payment Not Disclosed
Mid-Morning Market Update: Markets Edge Higher; Centene To Acquire Health Net For $6.3B
Integra LifeSciences Holdings' (IART) CEO Pete Arduini on Q2 2016 Results - Earnings Call Transcript (Seeking Alpha)

Integra LifeSciences Holdings Corporation (Nasdaq: IART) today announced that the Food and Drug Administration (FDA) has approved an expanded indication for use of the Integra® Vu aPOD™ Prime Intervertebral Body Fusion Device (IBD) in anterior lumbar interbody fusion (ALIF) procedures. The new stand-alone indication includes four points of fixation, which is composed of two screws and a SpinPlate™. The Integra® Vu aPOD™ Prime IBD will be featured at the Congress of Neurological Surgeons (CNS) annual meeting, October 6 – 10, 2012, in Chicago, Illinois.

Posted-In: News FDA

 

Related Articles (IART)

View Comments and Join the Discussion!